No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Renin-angiotensin-aldosterone system blockers are common in end-stage renal disease.
• Their cardiovascular benefits in this population remain unclear.
• Hemodialysis patients face high cardiovascular risk.

Purpose of the Study:

• To assess the long-term cardiovascular effects of irbesartan in hemodialysis patients.
• To evaluate irbesartan's impact on intermediate cardiovascular endpoints.
• To determine if irbesartan offers benefits beyond blood pressure reduction.

Main Methods:

• Double-blind, randomized, placebo-controlled 1-year trial (SAFIR study).
• 41 hemodialysis patients per group with a systolic blood pressure target of 140 mm Hg.
• Assessed brachial blood pressure, central aortic pressure, pulse wave velocity, left ventricular mass, and biomarkers.

Main Results:

• Both placebo and irbesartan groups showed significant brachial blood pressure reduction, with no difference between groups.
• No significant differences were observed in central hemodynamics, arterial stiffness, left ventricular mass, or cardiac biomarkers.
• Irbesartan did not significantly affect heart rate variability or plasma catecholamines.

Conclusions:

• Irbesartan demonstrated no significant effects on intermediate cardiovascular endpoints in hemodialysis patients beyond its blood pressure-lowering effect.
• Systolic blood pressure changes correlated with left ventricular mass and arterial stiffness, highlighting the importance of BP control.
• Further research may be needed to clarify the role of RAAS blockade in cardiovascular protection for ESRD patients.